[Problem] To provide a medium suitable for long-term storage, i.e., that ensures sufficient quality retention period, for growing obligate anaerobic bacteria or microaerobic bacteria under aerobic environment, and to provide a method of easily detecting obligate anaerobic bacteria or microaerobic bacteria using said medium. [Means for solving the problem] A long-term storage medium comprising dithiothreitol and/or ascorbic acid as a reducing agent in a basal medium, for culturing obligate anaerobic bacteria or microaerobic bacteria under aerobic environment, and a method of detecting obligate anaerobic bacteria or microaerobic bacteria using said medium.

There are provided compositions and methods for lyophilization and/or storage of live vaccine strains of Francisella tularensis. More specifically, there are provided lyophilization media and uses thereof for the preparation and long-term storage of Francisella tularensis vaccines.

The present invention provides a method of producing an osteoblast construct from human iPS cells, the method including the steps of: (1) inducing formation of an embryoid body by subjecting undifferentiated human iPS cells to non-adherent culture; (2) inducing differentiation of the human iPS cells into mesodermal cells by subjecting the embryoid body of the human iPS cells obtained in the step (1) to non-adherent culture; and (3) inducing differentiation into osteoblasts by subjecting the mesodermal cells of the human iPS cells obtained in the step (2) to non-adherent culture.

Provided herein are compositions including enucleated erythroid cells and methods of making and using the same.

The invention relates inter alia to a method for differentiating a muscle progenitor cell, comprising the step of: culturing a muscle progenitor cell in a serum-free medium for differentiating a muscle progenitor cell, wherein said serum-free medium comprises at least one differentiation inducer selected from the group consisting of a lysophosphatidic acid receptor 1 (LPAR1) agonist, a lysophosphatidic acid receptor 3 (LPAR3) agonist, an oxytocin receptor (OXTR) agonist, a glucagon receptor (GCGR) agonist, a lactate and a Notch signaling pathway inhibitor.

The subject invention concerns novel and translatable materials and methods for expansion of stem cells, such as mesenchymal stem cells (MSC), that significantly improve translational success of the cells in the treatment of various conditions, such as stroke. The subject invention utilizes cell self-aggregation as a non-genetic means to enhance their therapeutic potency in a microcarrier bioreactor. The subject invention integrates a cell aggregation process in a scalable bioreactor system. In one embodiment of the method, thermally responsive microcarriers (TRMs) are utilized in conjunction with a bioreactor system. Cells are cultured in a container or vessel in the presence of the TRMs wherein cells adhere to the surface of the TRMs. Once cells are adhered to the TRMs they can be cultured at a suitable temperature for cell growth and expansion, e.g., at about 37 C. After a period of time sufficient for cell growth and expansion on the TRMs, the cell culture temperature is reduced so that the cells detach from the TRMs. The detached cells are allowed to form cell clusters that are then cultured under conditions such that the clusters aggregate to form 3D aggregates. The 3D aggregates can be collected and treated to dissociate the cells (e.g., using enzymatic treatment, such as trypsinization). Dissociated cells can then be used for transplantation in methods of treatment or for in vitro characterization and study.

There is described a method for producing polymeric 3-hydroxypropionamide (3HP amide), the method comprising: culturing an Acetobacter lovaniensis-bacterium in a growth medium containing phosphate and ammonium, wherein culturing of the bacterium produces polymeric 3HP amide. The polymeric 3HP amide may then be hydrolysed to 3HP amide or converted to other compounds of interest.

The present invention relates to a three-dimensional (3D) tissue-like implant for transplanting to a subject in need comprising a cell cluster comprising mesenchymal stem cells (MSCs) and specific cells differentiated therefrom. The present invention also relate to a method of preparing a 3D-tissue-like implant from MSCs, particularly by seeding MSCs in alginate scaffolds and culturing the alginate scaffolds with MSCs in a 3-D perfusion condition. Further, the present invention provides a method for treating a defect in a recipient patient in need by administering a 3D tissue-like implant as described herein to the patient at a defective site e.g. a bone defective site.

The present invention relates to the field of fermentation biotechnology, more particularly to methods for the fermentative production of massoia lactone by Aureobasidium species.

A method for expanding a population of T-cells is provided in which isolated activated Peripheral Blood Mononuclear Cells (PBMCs) are cultured in a medium comprising transforming growth factor beta (TGF-) under conditions in which the production of effector T-cells having therapeutic activity against malignant disease is favored. The use of TGF- in the production of effector cells in particular V9V2 T-cells is also described and claimed.